Creative and innovative statistics in clinical research and development.

Area of Science:

• Pharmaceutical industry
• Clinical research and development
• Medical informatics

Background:

• The pharmaceutical industry faces declining new drug submissions.
• The US Food and Drug Administration's "Critical Path" initiative highlights challenges in clinical development.
• There's a need for innovative statistical methods in regulated drug development.

Purpose of the Study:

• To demonstrate opportunities for statisticians and medical informatics professionals in clinical research.
• To support the creative development and implementation of methods for clinical data.
• To enhance the collection, analysis, and interpretation of clinical data.

Main Methods:

• Review of the US Food and Drug Administration's "Critical Path" initiative.
• Presentation of innovative statistical approaches developed by industry and academia.
• Examples of novel methods for overcoming shortcomings in clinical development.

Main Results:

• Early Development: Combination of Bayesian methods and modeling enhances decision-making efficiency.
• Later Phases (IIb and III): Integrating modeling with frequentist approaches and adaptive designs optimizes dose regimen selection and trial efficiency.
• Novel adaptive designs improve trial execution and reduce timelines.

Conclusions:

• Combining established and novel statistical methods aligns with the "learning and confirming" paradigm in regulated development.
• New statistical approaches increase the efficiency of clinical development processes.
• Innovation in statistical methodology is crucial for pharmaceutical research.